The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin, cyclophosphamide (FEC) and docetaxel (D)

Vulsteke, Christof; Pfeil, AM; Schwenkglenks, M; Paridaens, Robert; Dieudonne, AS; Pettengell, R; Hatse, Sigrid; Neven, Patrick; Lambrechts, D; Wildiers, Hans

European Journal of Cancer

The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin, cyclophosphamide (FEC) and docetaxel (D)

Author:

Vulsteke, Christof

Pfeil, AM ; Schwenkglenks, M ; Paridaens, Robert ; Dieudonne, AS ; Pettengell, R ; Hatse, Sigrid ; Neven, Patrick ; Lambrechts, D ; Wildiers, Hans

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

European Journal of Cancer The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin, cyclophosphamide (FEC) and docetaxel (D)

Author:

Keywords:

European Journal of Cancer

The impact of baseline and genetic parameters on progression free survival and overall survival in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy with fluorouracil, epirubicin, cyclophosphamide (FEC) and docetaxel (D)